| Engerix-B (hepatitis B vaccine recombinant) / GSK |
NCT00697125: Immunogenicity & Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine With Different Adjuvants |
|
|
| Completed | 2 | 60 | Europe | Engerix™-B, HBV-MPL vaccine (208129), Hepatitis B vaccine, experimental formulation | GlaxoSmithKline | Hepatitis B | 07/94 | 07/94 | | |
NCT00697229: Immunogenicity & Reactogenicity of HBV-MPL Vaccine and Engerix™-B in Healthy Adults Following 2 Different Schedules |
|
|
| Completed | 2 | 99 | Europe | Engerix™-B, HBV-MPL vaccine | GlaxoSmithKline | Hepatitis B | 05/96 | 12/98 | | |
NCT00698906: Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 19-40 y |
|
|
| Completed | 2 | 160 | Europe | HBV-MPL vaccine, Engerix™-B | GlaxoSmithKline | Hepatitis B | 02/98 | | | |
NCT00698555: Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 18-40 y |
|
|
| Completed | 2 | 163 | Europe | HBV-MPL vaccine, Engerix™-B | GlaxoSmithKline | Hepatitis B | 05/98 | | | |
NCT00697775: Safety and Immunogenicity of GSK Bio's Candidate HBV-MPL Vaccines Compared to Engerix™-B, in Healthy Adolescents |
|
|
| Completed | 2 | 200 | Europe | HBV-MPL vaccine Formulation A, HBV-MPL vaccine Formulation B, Engerix™-B | GlaxoSmithKline | Hepatitis B | 05/99 | | | |
NCT00697853: Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine (2 Doses), and of Engerix™-B (3 Doses) in Healthy Adults |
|
|
| Completed | 2 | 200 | Europe | Engerix™-B, HBV-MPL vaccine 208129 | GlaxoSmithKline | Hepatitis B | 07/99 | | | |
NCT01457495: Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly |
|
|
| Completed | 2 | 312 | NA | DTPa-HBV-IPV/Hib (Infanrix-hexa™), DTPa-IPV/Hib (Infanrix-IPV/Hib™), HBV (Engerix™-B) | GlaxoSmithKline | Hepatitis B, Diphtheria, Haemophilus Influenzae Type b (Hib), Poliomyelitis, Pertussis, Tetanus | 09/99 | 09/99 | | |
NCT00805389 / 2008-004455-29: Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With the Antigen of the Hepatitis B Vaccine |
|
|
| Completed | 2 | 713 | Europe | Engerix-B™, Fendrix™, GSK Biologicals' Hepatitis B vaccines (GSK223192A), HBsAg (Booster injection) | GlaxoSmithKline | Hepatitis B | 09/10 | 07/11 | | |
NCT01777295 / 2012-001344-22: Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen (HBsAg) in Combination With a GlaxoSmithKline (GSK) Biologicals' Adjuvant System |
|
|
| Completed | 2 | 81 | Europe | Adjuvanted Hepatitis B surface antigen (HBsAg) candidate vaccine GSK2231392A., HBsAg/AS, EngerixTM-B, Engerix-B, Placebo | GlaxoSmithKline, Region of Wallonia, Public Private Partnership with Institute for Medical Immunology (Universite Libre de Bruxelles) | Hepatitis B | 05/16 | 09/16 | | |
